Merck signs up to $3.3 bln cancer drug deal with China-based LaNova
Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...
Why Are These 3 Vanguard ETFs Underperforming the S&P 500 Since Election Day?
The S&P 500 rallied in the wake of last week's election results, climbing 3.8% since Nov. 5 at Wednesday's prices. But not ...
Merck & Co., Inc. (MRK): Among the Best Low Volatility Stocks to Invest In Now
We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...
Russia says African, ex-Soviet countries interested in its mpox vaccine
Several African and ex-Soviet countries have expressed interest in buying Russia's vaccine against smallpox and mpox viruses, ...
pharmaphorum4d
Takeda agrees $2.3bn sale of Japanese consumer health unit
Other companies that have been exiting the consumer health business in recent years include Novartis, Merck KGaA, and Bristol-Myers Squibb as well as Pfizer and GlaxoSmithKline which have agreed ...
pharmaphorum1d
After cough drug setback, Merck partners Hyfe's tracking app
Merck & Co has signed a deal with digital health firm Hyfe that will see its ... as a cough frequency tool that can be added into its consumer disease educational efforts. It's worth noting ...
FDA wants to pull decongestant found in many cold, allergy medicines
The FDA is proposing the removal of phenylephrine, a popular nasal decongestant, in oral form from over-the-counter use. Here ...
A Popular Decongestant Doesn’t Work. The FDA Is Finally Doing Something About It
Oral phenylephrine was shown to be ineffective for treating nasal congestion over a year go. This week, the FDA took the ...